{
    "medicine_id": "c57b6ae065f20314f4b4deab04fcdec33d14da51",
    "platform_id": "DB04970",
    "metadata": {
        "name": "Potiga 50 mg 1 Tablet film coated",
        "composition": "50 mg 1 Lesopitron",
        "clinical_particulars": {
            "therapeutic_indications": "Intended for the treatment of anxiety disorders",
            "contraindications": {
                "disease": "The most commonly reported adverse events in all the panels in one study were headache dizziness and nausea PMID 8959472",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "In phase I trials in healthy volunteers lesopitron was well tolerated in single doses up to 50 mg and up to 45 mg day in repeated doses Lesopitron has negligible effects on alpha adrenergic and dopaminergic receptors and was more potent than structurally related 5 HT1A agonists in rat social interaction and marmoset anxiety models It also countered benzodiazepine withdrawal induced anxiety in rodents The acute toxicity of lesopitron is low and it does not potentiate the effects of alcohol or barbiturates Long term usage led to reductions in plasma glucose triglycerides phospholipids and cholesterol",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}